Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
Continue Reading
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business24 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News22 hours agoE-biker charged with riding dangerously, assaulting cop
-
General20 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands